DaVita Venture Group

What DaVita Venture Group does

DaVita Venture Group is the corporate venture capital and strategic investment arm of DaVita Inc. (NYSE: DVA), one of the largest dialysis providers in the United States. The group was founded to invest in, develop, and launch products, solutions, and businesses that improve care for patients with kidney disease, operating out of Denver with 11-50 employees. Its capital is deployed across four investment priorities — Care Models (tech-enabled services, home treatments, value-based care), Digital Health (data and artificial intelligence for care delivery), New Service Lines (extending DaVita's clinical excellence to adjacent verticals), and Life Sciences (pharma, devices, and diagnostics) — with an active portfolio of nine companies and three realized exits.

The group operates three core capabilities: a Venture Capital function deploying up to $10 million per deal on a stage-agnostic basis, a Corporate Development function executing scale investments, acquisitions, and joint ventures, and a Strategic Partnerships function that co-develops, pilots, and incubates new care models and technologies. Active portfolio companies span hyperphosphatemia therapeutics (R1 Therapeutics, Pathalys), value-based primary care (Greater Good Health), AI-backed CHF care (Linea), xenotransplantation (Egenesis), vascular devices (Xeltis), women's health devices (X9/ExploraMed), transplant logistics (Medsleuth), advance care planning (Vynca), cardiology (Heartbeat), and behavior change (Wellth), with strategic co-development underway in kidney-specific home care with Elara Caring.

The business model is a corporate venture platform rather than a fee-generating asset manager. DaVita Venture Group does not publicly disclose pricing, fund size, or standalone revenue, and its economics flow through DaVita Inc.'s consolidated financials. Its go-to-market is direct engagement with healthcare innovators, executed by a team of approximately 18 investment, strategy, and corporate development professionals supported by Group General Counsel, with go-to-market communications concentrated on LinkedIn and the DaVita corporate website. The group's core value proposition to founders is access to DaVita's clinical expertise, patient cohorts, and distribution channels — assets that third-party VCs cannot replicate.

Name

DaVita Venture Group

Legal name

DaVita Inc.

Website

https://davitaventuregroup.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

DaVita Venture Group is the corporate venture capital and strategic investment arm of DaVita Inc., deploying up to $10 million per deal across kidney care, digital health, life sciences, and adjacent healthcare verticals to improve outcomes for patients with kidney disease.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industries

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD), Corporate M&A / Venture Build-to-Buy Programs (Acqui-hire, option-to-acquire) (FSANAHAG)

Keywords

• Corporate venture capital
• Healthcare venture investing
• Kidney care innovation
• Strategic investment partnerships
• Medical technology investment

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Distribution channels1 record

Marketing channels1 record

Core offering

DaVita Venture Group is the corporate venture capital and strategic investment arm of DaVita Inc., investing up to $10 million per deal in companies developing innovations for kidney disease and adjacent healthcare verticals. It executes venture capital, corporate development transactions (scale investments, acquisitions, joint ventures), and strategic partnerships to co-develop, pilot, and incubate new care models and technologies. The group focuses on four investment priorities: Care Models, Digital Health, New Service Lines, and Life Sciences.

Product overview

DaVita Venture Group is a venture capital and strategic investment arm of DaVita, functioning as a multi-product investment platform. The organization offers three core investment vehicles: Venture Capital (investing up to $10M per deal, stage agnostic), Corporate Development (managing scale investments, acquisitions, and joint ventures), and Strategic Partnerships (co-developing, piloting, and incubating new care models and technologies). The investment thesis spans four verticals: Care Models (tech-enabled services, home treatments, value-based care), Digital Health (AI and data solutions), New Service Lines (adjacent care verticals), and Life Sciences (pharma, devices, diagnostics). The portfolio includes active investments in Greater Good Health, R1 Therapeutics, Linea, Egenesis, Xeltis, X9, Medsleuth, Vynca, Pathalys, Heartbeat, and Wellth, along with exited investments in Dock Health, Miromatrix, and Samesky health.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital
• Corporate Development
• Strategic Partnerships

Quantifiable outcome

• DaVita's collaboration with Linea demonstrated 50% reduction in hospital readmissions and 80% patient engagement rates

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and major.

• LineacoreStrategic or Co-development PartnerDaVita collaborates with Linea, an AI-backed care platform for congestive heart failure, which has demonstrated early results including 50% reduction in hospital readmissions and 80% patient engagement rates. DaVita uses Linea to complement clinical teams with predictive insights.
• Elara CaringmajorStrategic or Co-development PartnerDaVita invested in Elara Caring and announced a partnership to co-develop a kidney-specific home care model. Elara Caring is a Dallas-based provider of skilled home health, hospice, behavioral health, and personal care services serving more than 60,000 patients daily across 200 locations in 18 states.
• Alebund PharmaceuticalscoreStrategic or Co-development PartnerR1 Therapeutics secured exclusive global development and commercial rights outside of Greater China for AP306 from Alebund Pharmaceuticals, with potential milestone payments up to low triple-digit millions and tiered royalties in low double-digit percentages. Alebund retains rights in Greater China.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Novartis Venture Fund: Corporate venture arm of Novartis investing in life sciences and adjacent verticals. Comparable as a strategic CVC from a healthcare parent that invests stage-agnostically into therapeutic and care-model innovation, though tilted toward pharma R&D.
• Kaiser Permanente Ventures: Strategic venture arm of Kaiser Permanente, focused on healthcare technology and services investments that align with the integrated care-delivery model's strategic priorities. Comparable as a healthcare-vertical CVC backed by a major care-delivery platform.
• Pfizer Ventures: Corporate venture arm of Pfizer making equity investments in emerging companies across therapeutic areas. Comparable to DaVita Venture Group's Life Sciences thesis as a pharma-backed CVC deploying strategic capital into clinical-stage innovation.
• Providence Ventures: Strategic venture arm of Providence Health, focused on digital health, care delivery, and therapeutic innovations. Comparable as a non-profit health-system CVC pursuing similar themes around value-based care, digital health, and new care models.
• Fresenius Medical Care Ventures: Corporate venture and innovation arm of Fresenius Medical Care, the other dominant global dialysis provider. Highly comparable to DaVita Venture Group as a strategic CVC operating in the same kidney-care vertical with similar clinical distribution advantages.

Broad incumbents

• Johnson & Johnson Innovation: Strategic innovation and venture arm of J&J investing across pharma, medtech, and consumer health. Comparable to DaVita Venture Group as a large healthcare CVC that combines venture investing with co-development and incubation.
• Bristol-Myers Squibb (Celgene) Ventures: Strategic venture and corporate development activities of BMS (including legacy Celgene Ventures) investing in therapeutics and biotech. Comparable to DaVita Venture Group's Life Sciences focus as a pharma CVC with clinical-stage exposure.
• Anthem (Elevance Health) Ventures: Strategic investment and partnership activities of Elevance Health (formerly Anthem), spanning payer, care-delivery, and digital health. Comparable as a large payer-backed strategic investor pursuing value-based care and digital health themes.
• UnitedHealth Group Ventures (Optum Ventures): Corporate venture arm of UnitedHealth/Optum that invests across healthcare services, digital health, and care delivery. Comparable to DaVita Venture Group as a large strategic CVC that leverages a parent company's clinical infrastructure to deploy capital into healthcare innovation.

Emerging players

• Memorial Hermann Health System Ventures: Health-system venture and innovation activities of Memorial Hermann. Comparable as an emerging health-system CVC focused on care-model and digital health investments that benefit from parent clinical infrastructure, though at smaller scale than DaVita Venture Group.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xtwitter.com/DaVita
• YouTubeyoutube.com/user/DaVitaKidneyCare
• Facebookfacebook.com/davitakidneycare
• LinkedInlinkedin.com/company/davita-venture-group
• Instagraminstagram.com/davita

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DaVita Venture Group